Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All povidone‑iodine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPVP-IPovidone-Iod.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Tolerability and usability of 0.5% PVP-I gargles and nasal drops in 6692 patients: Observational study

Khan et al., American Journal of Otolaryngology, doi:10.1016/j.amjoto.2020.102880
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
PVP-I for COVID-19
13th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000000037 from 20 studies.
Lower risk for mortality, cases, and viral clearance.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Study of the use of PVP-I gargles and nasal drops before and after ENT examinations with a total of 6,692 patients, finding high usability and good tolerance for use.
21 patients (0.76%) reported an itching sensation in the nose on the first day of use of 0.5% PVP-I nasal drops and discontinued its further use. However, none of the patients reported any serious side effects or allergic reaction to 0.5% PVP-I nasal drops and gargles.
The 0.5% PVP-I gargles and nasal drops were used by healthcare workers about three to four times in a day for 5 months. None of them developed any COVID-19 symptoms.
Khan et al., 3 Jan 2021, peer-reviewed, 2 authors.
This PaperPovidone-Iod..All
Tolerability and usability of 0.5% PVP-I gargles and nasal drops in 6692 patients: Observational study
Sapna Mubarak Muhamed Khan, Sapna Ramkrishna Parab
American Journal of Otolaryngology, doi:10.1016/j.amjoto.2020.102880
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
References
Ader, Paul, Reinhardt, Effect of mouth rinsing with two polyvinylpyrrolidone-iodine mixtures on iodine absorption and thyroid function, J Clin Endocrinol Metab
Domingo, Farrales, Loya, Pura, Uy, The effect of 1% povidone iodine as a pre-procedural mouthrinse in 20 patients with varying degrees of oral hygiene, J Philipp Dent Assoc
Eggers, Eickmann, Zorn, Rapid and effective Virucidal activity of povidoneiodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified Vaccinia virus Ankara (MVA), Infect Dis Ther, doi:10.1007/s40121-015-0091-9
Eggers, Infectious disease management and control with povidone iodine, Infect Dis Ther
Eggers, Koburger-Janssen, Eickmann, Zorn, In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens, Infect Dis Ther, doi:10.1007/s40121-018-0200-7
Khan, Parab, 0.5% povidone iodine irrigation in otorhinolaryngology surgical practice during COVID 19 pandemic, Am J Otolaryngol, doi:10.1016/j.amjoto.2020.102687
Khan, Parab, Paranjape, Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in covid 19 pandemic, Am J Otolaryngol, doi:10.1016/j.amjoto.2020.102618
Lachapelle, Castel, Casado, Antiseptics in the era of bacterial resistance: a focus on povidone iodine, Future Med
Madan, Sequeira, Shenoy, Shetty, The effect of three mouthwashes on radiation-induced oral mucositis in patients with head and neck malignancies: a randomized control trial, J Cancer Res Ther
Mullings, Panchmatia, Samoy, Topical povidone-iodine as an adjunctive treatment for recalcitrant chronic rhinosinusitis, European Journal of Rhinology and Allergy, doi:10.5152/ejra.2019.166
Nagatake, Ahmed, Oishi, Prevention of respiratory infections by povidoneiodine gargle, Dermatology
Panchmatia, Payandeh, Al-Salman, The efficacy of diluted topical povidone-iodine rinses in the management of recalcitrant chronic rhinosinusitis: a prospective cohort study, Eur Arch Otorhinolaryngol Published Online First, doi:10.1007/s00405-019-05628-w
Rackur, New aspects of mechanism of action of povidoneiodine, J Hosp Infect
Rahn, Adamietz, Boettcher, Schaefer, Reimer et al., Povidoneiodine to prevent mucositis in patients during antineoplastic radiochemotherapy, Dermatology
Reimer, Wichelhaus, Schafer, Antimicrobial effectiveness of povidoneiodine and consequences for new application areas, Dermatology
Rezapoor, Nicholson, Tabatabaee, Chen, Maltenfort et al., Povidone-iodine-based solutions for decolonization of nasal Staphylococcus aureus: a randomized, prospective, placebo-controlled study, J Arthroplasty, doi:10.1016/j.arth.2017.04.039
Sungnak, Huang, 'ecavin, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat Med
Wewalka, Stary, Bosse, Duerr, Reimer, Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis, Dermatology
Zou, Ruan, Huang, SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N Engl J Med
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit